Introduction
The ability of donor lymphocyte infusions (DLIs) to induce complete remissions of chronic myeloid leukemia in patients relapsing after allogeneic bone marrow transplantation (alloBMT) has provided the most direct clinical evidence for the existence of the T-cell-mediated graft versus-leukemia (GVL) effect.
1,2 Unfortunately, the efficacy of DLI in the treatment of other relapsed hematologic malignancies after alloBMT is much lower. While several different approaches to separate the GVL effect from graf-versus-host disease (GVHD) have achieved some clinical success, [3] [4] [5] [6] [7] [8] the underlying immunologic mechanisms of the improved outcomes remain poorly defined. 9 An understanding of the factors and mechanisms that govern the DLI-derived T-cell-mediated immune responses may be critical for both decreasing GVHD and optimizing their antitumor efficacy.
The induction of allogeneic T-cell responses requires an encounter between lymphocytes and
antigen-presenting cells (APCs) in secondary lymphoid tissues. 10, 11 The critical role of host versus donor APCs in initiating and/or sustaining GVHD and the GVL effect in mice immediately after conditioning has been a focus of recent extensive studies led by several groups of investigators. [12] [13] [14] [15] [16] [17] However, T-cell-APC interactions late after transplantation are less well understood and in part may differ from those immediately after conditioning, since DLI-mediated graft-versus-host (GVH) and GVL reactivities can be achieved without GVHD. 15, 18 This is because reconstituted donor-derived and residual host-derived dendritic cells (DCs) may be present to varying degrees, the conditioning-induced inflammatory response has subsided, tolerance may have been established and immunoregulatory networks may exist. [18] [19] [20] These factors may have a profound influence on the ability of T-cells infused late after transplantation to mediate the GVL effect and/or GVHD. We demonstrate here that the contribution of these factors in governing DLI-derived T-cell-mediated alloimmune responses in the MHC-matched and -mismatched only.
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Materials and methods
Mice. C57BL/6 (B6; (10 7 ) and host (5 x 10 6 ) bone marrow cells (BM) cells, while "full" chimeras were constructed by reconstituting lethally irradiated recipients with TCD donor (10 7 -1.5 x 10 7 ) BM cells only, unless otherwise noted. 15, 21 TCD of BM was performed as previously described. 22 DLI consisted of 2 x 10 7 donor splenocytes, unless otherwise noted.
CFSE (Molecular Probes, Eugene, OR) labeling of DLI was performed as previously described. 23 For presenzitation of donors against BALB/c alloantigens, B10.D2 mice were either primed intraperitoneally (i.p.) with BALB/c splenocytes or received full thickness skin grafts. 24, 25 The stimulatory and control only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From CpG oligodeoxynucleotides (ODNs) used in this study were CpG1826 (5'-TCCATGACGTTCCTGACGTT3') and CpG1982 (5'-TCCAGGACTTCTCTCAGGTT3'), respectively. 26 Flow cytometric analysis. Spleens, LNs or peripheral blood were obtained and prepared for flowcytometry as previously described. 22 The mAbs used were biotinylated or fluorochrome-conjugated anti- were acquired on FACSCalibur flow cytometer (BD Biosciences) and were analyzed using FlowJo software (Tree Star, Ashland, OR). To determine IFN-γ production, cells were stimulated with 4α-phorbol-12-myristate-13-acetate (PMA; 3 ng/ml) and ionomycin (500 ng/ml; Sigma-Aldrich) for 5h in culture in the presence of GolgiStop (BD Biosciences). Thereafter cells were stained according to the manufacturer's protocol (CytoFix/CytoPerm kit, BD Biosciences).
Statistical analysis
Data were analyzed using PRISM software (version 4.0; GraphPad, San Diego, CA). Values are presented as the mean ± SEM. The statistical differences were calculated using Student's two tailed t test. A value of P <0.05 was considered statistically significant.
Results
The residual host chimerism influences the potency of DLI-mediated GVH reactivity only in the
MHC-mismatched but not MHC-matched setting
To determine the role of residual host APCs on the DLI-mediated LH-GVH response in the MHCmatched and -mismatched setting, "mixed" and "full" chimeras with a different amounts of residual host chimerism were constructed. 15, 21 To distinguish the origin of DCs in MHC-matched, mHAg-mismatched setting we relied on the differential expression of alleles of CD45, the Common Leukocyte Antigen. As depicted in Fig. 1A (Table I) . Conversely, presensitized DLI-derived CD8 + T-cells in mixed (P <0.05) and both CD4 + and CD8 + T-cells in full (P <0.05 for CD4 and CD8) chimeras divided faster than naïve DLIderived T-cells (data not shown). Despite the more prominent in vivo proliferation of presenzitized CD8 + T-cells in the both sets of chimeras (data not shown) the total number of DLI-derived CD8 + T-cells was statistically higher only in full but not in the mixed chimeras (Table I; only.
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Timing of DLI administration is critical factor governing the DLI-mediated LH-GVH reactivity in

MHC-matched, mHAg-mismatched chimeras
The failure of naïve DLI to eradicate residual host T-cells in 8-week-old full chimeras (Fig. 2 C) is in direct contrast to the original studies conducted by Johnson et al, 18, 35 showing that DLI administration 3 weeks after MHC-matched, mHAg-mismatched alloBMT results in conversion to full donor T-cell chimerism. We hypothesized that different outcome is most likely the result of more vigorous clonal expansion and higher IFN-γ production by DLI-derived T-cells in early in contrast to the late (>8-weekold) chimeras. To test this hypothesis in vivo, we compared the expansion of DLI-derived T-cells in B10.D2→BALB/c full chimeras that received DLI early (3-4 weeks) or late (8-12 weeks) after alloBMT.
We found significantly higher expansion of DLI-derived T-cells in chimeras that received DLI early vs late after alloBMT (P <0.05, data not shown) consistent with our recent findings in B6→C3H.SW, MHCmatched, mHAg-mismatched model. 29 In addition, significantly higher numbers of DLI-derived T-cells For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From and secondary lymphoid tissues, since their presence can be detected for at least 3 weeks in the BM and spleen of the chimeras (Fig. 2F) . Thus, in MHC-matched setting other factors rather than amount of host DCs influence the superior DLI-mediated alloreactivity in early chimeras. Next we examined requirements governing the DLI-mediated alloreactivity in early and late full vs mixed chimeras.
In vivo activation of APCs with TLR ligands augments the potency of DLI in early MHC-matched, mHAg-mismatched full chimeras
Since the priming of naïve T-cells depends on the maturation status of APCs, 37, 38 we hypothesized that the potency of DLI-mediated alloreactivity could be influenced by the activation status of APCs that they encounter in the chimeras. To test our hypothesis, we focused on two approaches: (a) to administer For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From mediated GVH response was influenced by the in vivo activation of APCs. To determine whether that effect can be mediated by other TLR ligands, we used imiquimod, a known synthetic ligand for TLR7. 44 Imiquimod is presumed to act by inducing the secretion of proinflammatory cytokines such as IFN-α, tumor necrosis factor-α, IL-6, and IL-12 in the skin. 45, 46 This locally generated cytokine milieu induces emigration of skin-derived DCs (in this model majority of the skin-derived CD11c + DCs are hostderived; Ref. 29 ) and biases toward a Th1 cell-mediated immune response, with the generation of cytotoxic effectors. 47 Imiquimod was topically administered to the shaved skin (approximately 1 square inch) of the C3H.SW→B6 chimeras for 3 days prior to and on the day of the DLI administration. The conversion to full donor CD8 + T-cell chimerism occurred only in chimeras that received imiquimod with DLI (P <0.001; Fig. 3B ).
To directly examine the effect of imiquimod on DCs, we examined CD11c + DCs from CLNs draining the treated area of skin. We observed that CLN size, total cellularity, and number of both host and donor CD11c + DCs were significantly higher in the imiquimod-treated 4-week-old C3H.SW→B6.SJL chimeras (Fig. 3C) . Consistent with our previous findings, 29 we found that host-derived CD11c + DCs, representing mostly epithelium-derived CD11c + DCs (epDCs), express higher levels of CD40 and CD86 in steady state than donor CD11c + DCs in untreated chimeras (Fig. 3D) . Upon imiquimod treatment, the expression of CD40 and CD86 on both host and donor DCs increased ( Fig. 3D ; P <0.05; untreated vs imiquimod-treated, for mean fluorescence intensity (MFI), both CD40 and CD86). The observed effect was also reflected in the increased number of CD11c + DCs having mature phenotype (P <0.005; for both CD40 and CD86; Fig. 3 E, F) . The effect of imiquimod was not restricted to DCs, since recently described interferon-producing killer DCs (IKDCs) 48 and host B cells were recruited to the CLNs as well (Fig. 3G,   H ).
only.
Combined-TLR ligation or depletion of host T-cells together with TLR activation of DCs is required to augment the DLI-mediated GVH reactivity in late full or early mixed MHC-matched chimeras
We recently reported that administration of imiquimod with DLI to 8-week-old full chimeras augmented the LH-GVH reactivity of DLI-derived T-cells, however, the effect was not potent enough to induce complete conversion to full donor chimerism. 29 We also found that in 8-week-old chimeras administration of CpG1826 ODNs with DLI is ineffective in inducing conversion to full donor T-cell chimerism (data not shown). Thus, we hypothesized that insufficient DLI-mediated alloreactivity in 8 and data not shown). Since synergistic TLR stimulation is known to result in more potent APC maturation program, 50,51 we next administered TLR7 and 9 ligands together with DLI to 8-week-old chimeras.
Combined TLR activation of DCs augmented LH-GVH reactivity of DLI resulting in complete conversion to full donor T-cell chimerism (P <0.005 for CD4 and P <0.05 for CD8; Fig. 4B ). These results strongly support our hypothesis that the activation status of APCs encountered by adoptively transferred T-cells can critically influence the DLI-mediated LH-GVH response and that more potent APC activation is required in 8-week-old chimeras. Despite transient weight loss in chimeras treated with both TLR ligands, no obvious clinical signs of GVHD were observed (Fig. 4C) .
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We next sought to determine whether the in vivo DC activation influences the DLI-mediated GVH reactivity in MHC-matched mixed chimeras. Four-week-old B10.D2 + BALB/c→BALB/c mixed chimeras received DLI alone or in combination with CpG1826 ODNs. In contrast to findings with 4-week-old full chimeras described above, coadministration of DLI with CpG1826 ODNs was ineffective in augmenting the LH-GVH reactivity of DLI in mixed chimeras (data not shown). The inability of DLIderived T-cells to perturb the state of tolerance and induce LH-GVH reactivity despite the presence of large numbers of professional host-derived APCs and coadministration of TLR9 ligand led us to examine the role of suppressive mechanisms in mixed chimeras. As depicted in Fig. 4D , administration of anti-CD25 mAb was ineffective in augmenting DLI-mediated LH-GVH reactivity measured as changes in
CD4
+ and granulocyte chimerism. Since host T-cells can limit DLI-mediated alloimmune responses, 27 we next selectively depleted them in vivo, using anti-Thy1.2 mAb given to B10.D2-Thy1.1 + BALB/c-CD45.1 (Thy1.2)→BALB/c-CD45.1 mixed chimeras prior to DLI with or without CpG1826 ODNs. The anti-Thy1.2 treatment resulted in near complete conversion to full donor T-cell chimerism. However, significant increase in donor granulocyte chimerism reflective of LH-GVH response was observed only in anti-Thy1.2-treated chimeras if the DLI was coadministered with CpG1826 ODNs (P <0.05; Fig. 4D) suggesting the critical need to activate APCs.
In vivo activation of APCs augments GVL reactivity of DLI administered to MHC-matched full donor chimeras
Based on the above results, we hypothesized that augmented LH-GVH reactivity of DLI after systemic activation of APCs should translate into better GVL reactivity. Therefore, using a tumor- Fig. 5A ). However, administration of CpG1826 ODNs with DLI significantly improved survival of the chimeras over those that received DLI only (P <0.001) or DLI coadministered with host DCs (P <0.001; Fig. 5A ). The next series of experiments were designed to test whether imiquimod augments the GVL effect. Consistent with chimerism results presented earlier, the administration of imiquimod with DLI resulted in significantly improved survival of chimeras (P <0.002; Fig. 5B ). From these results we conclude that the combined administration of DLI and in vivo activation of APCs is a highly potent strategy to stimulate GVL reactivity if administered to full chimeras early after MHC-matched alloBMT.
Since 4-week-old chimeras are still lymphopenic, and therefore, contain stimuli for homeostatic proliferation of adoptively transferred T cells that may contribute to the antitumor immunity, 53 we next sought to dissociate the contribution of this mechanism from the GVL effect driven by mHAg disparity.
To accomplish this, syngeneic B6→B6 chimeras, constructed after lethal irradiation and transplantation of syngeneic BM cells, received 2 x 10 7 B6 splenocytes in the form of DLI alone or together with imiquimod followed by the lethal dose of C1498 leukemia. Both groups of syngeneic chimeras rapidly succumbed to the C1498 leukemia in contrast to the allogeneic chimeras that received DLI and imiquimod, thus confirming that donor T-cells recognizing host mHAgs were primarily responsible for GVL effect (P <0.002; Fig. 5C ).
To determine whether this strategy is effective in augmenting the GVL response in late chimeras, C3H.SW→B6 full chimeras 8 weeks after alloBMT received DLI and were treated with anti-CD25 mAb or imiquimod alone or with a combination of imiquimod and CpG1826 ODNs. All chimeras were challenged with 5 x 10 4 C1498 leukemia cells seven days after DLI. In vivo depletion of CD25 + cells only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From before DLI had no effect while imiquimod provided minimal survival benefit over DLI alone (P =NS; Fig.   5D ). However, coadministration of imiquimod and CpG1826 ODNs with DLI significantly increased their GVL reactivity (P <0.001; Fig. 5D ). We did not observed any clinical signs of GVHD in CpG1826
ODNs-and imiquimod-treated 8-week-old chimeras.
Discussion
With the development of reduced intensity conditioning regimens and more effective strategies for GVHD prophylaxis, attention has increasingly focused on developing strategies to prevent or control progression of the underlying malignancy, the most common cause of failure of alloBMT. Presently, DLI is the treatment of choice for leukemia in relapse after alloBMT. 2, 9, 31 Several studies have endeavored to elucidate the parameters governing the potency of GVH and GVL responses after alloBMT or DLI. rarely responded. 31, 55 Our studies demonstrate that the outcome of DLI is determined by factors intrinsic to the donor Tcell population as well as characteristics of the transplanted host. On the T-cell side, a more potent LH-GVH response after MHC-mismatched as compared to MHC-matched DLI can be explained by the higher precursor frequency of alloreactive T-cells and possibly a higher proportion of alloreactive memory T- The second possible mechanism is that donor T-cells become "exhausted" by a high dose of disseminated antigen [62] [63] [64] , even when and perhaps because host DCs are abundant. Therefore, and in agreement with the clinical observations, MHC-matched, mHAg-mismatched DLI-mediated alloimune responses are most effective if DLI is administered early after conditioning in the presence of low <15% but not high >40% amounts of residual host chimerism. 31, 55 The series of experiments performed by Rocha et al. 65 using a minor antigen-mismatched (H-Y-mismatched) transgenic system supports the latter explanation. Finally, the augmentation of DLI-mediated GVH and GVL responses by administration of TLR agonists raises the possibility that the activation of donor T-cells is governed to some extent by the maturation status of host APCs.
Comparisons of the factors characterized in this study with those of previously published studies may help reveal important aspects of DLI-mediated GVH reactions after alloBMT. For example, it has been suggested that MHC-mismatched DLI mediates superior GVL effects in mixed compared to full donor chimeras. 15 Although our results confirm that mixed chimerism is predictive of a more powerful only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From DLI-mediated LH-GVH effect (a potential surrogate for GVL reactivity) in the MHC-mismatched setting, they also demonstrate that this is not the case in the MHC-matched mixed chimeras where > 40% of professional APCs are host derived, and as such, capable of directly presenting host mHAgs to DLIderived T cells. Billiau at al. 36 have identified the timing of DLI administration as a critical factor for the induction of optimal LH-GVH and GVL reactions. Our studies extend this finding by showing that the activation status of the APCs rather than amount of residual host DCs is critically important for DLImediated alloreactivity in both early and late chimeras. However, whereas topical application or systemic administration of TLR ligands promoted GVHD after MHC-mismatched DLI, 42, 66 the same treatment combined with MHC-matched DLI was able to induce LH-GVH and GVL reactivities without causing clinical GVHD (Fig. 3-5 and Ref. 29 ). In contrast, the combination of MHC-matched DLI and For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From environmental antigenic exposures, to the freely available endogenous and exogenous TLR ligands in the transplanted host as a result of the concomitant infections and/or damaged epithelial surfaces and tissues caused by chemotherapy given to control relapsed underlying malignancy.
Our finding that TLR ligands augment GVH and GVL reactivity of DLI extends the emerging data suggesting that TLR-mediated signaling is important for T-cell alloimmunity. 70 Furthermore, our data clearly show that TLR-augmented GVL reactivity of DLIs administered to established chimeras is mediated primarily by anti-mHAgs responses (Fig. 5C .) The inability of ex vivo-matured host DCs to significantly influence the DLI-mediated alloimmune responses is consistent with other studies in a nontransplant setting showing that in vivo triggering of DC maturation with TLR ligands is a superior strategy for manipulating T-cell responses. 71 This sustained signaling may result in a better "maturation" state of DCs due to the known ability of TLRs to up-regulate all three categories of positive signals that DCs deliver to T-cells: antigen, costimulation, and cytokines. 72, 73 Finally, our finding that TLR ligands augment the GVL effect of MHC-matched DLI without inducing lethal GVHD is highly relevant for studies after HLA-matched nonmyeloablative allografting in which conversion to complete donor T-cell chimerism, known to be associated with achievement of disease remission, may be delayed, 74, 75 or for improving the relatively low efficacy of DLI in the treatment of aggressive malignancies, such as acute leukemia, in relapse after HLA-matched alloBMT.
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For The absolute number of DLI-derived Thy 1.1 + T-cells was calculated on days +5, +12 and +29 after DLI (2 x 10 7 B10.D2-Thy1.1 splenocytes) by multiplying the total number of viable cells by the percentages of gated CD4 + or CD8 + T-cells co-expressing CD90.1 marker, respectively (n=3-4 chimeras/time point and group).
# P <0.05; between the B10.D2→BALB/c group that received presensitized DLI vs other groups.
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